Prescription injection recalled for failed stability test results
Teva Pharmaceuticals is recalling Granix injection due to failed stability test results showing one peptide did not meet specification limits.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II designation with failed stability specifications for a prescription injectable drug represents a risk-of-harm situation where no illnesses or injuries have been reported. The failed stability test indicates the product may not maintain proper potency or acceptable stability characteristics over its shelf life.
Plain-English summary
Teva Pharmaceuticals USA, Inc. is recalling certain batches of Granix (tbo-filgrastim) Injection 300 mcg/0.5 mL. A 12-month stability test revealed that one of the known peptides in the affected product fell below the specification limit.
The recall includes 34,636 cartons that were distributed nationwide. The affected lot numbers are 135738, 137149, and 137148, each with an expiration date of 09/30/2025.
Granix is a prescription injectable medication. The FDA classified this as a Class II recall. The product was manufactured by UAB Teva Baltics in Lithuania and distributed by Teva Pharmaceuticals USA, Inc.
The recalled product
- Product
- GRANIX (TBO-FILGRASTIM)
- Brand
- GRANIX
- Manufacturer
- Teva Pharmaceuticals USA, Inc
- Category
- Drug — Injectable Growth Factor
- Hazard
- stability-failure
- reduced-potency
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot # (a) 135738
- (b) 137149
- (c) 137148
- Exp. date 09/30/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27